COSCIENS Biopharma Correlations
| CSCI Stock | 2.86 0.75 35.55% |
The correlation of COSCIENS Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
COSCIENS Biopharma Correlation With Market
Modest diversification
The correlation between COSCIENS Biopharma and DJI is 0.25 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding COSCIENS Biopharma and DJI in the same portfolio, assuming nothing else is changed.
Moving together with COSCIENS Stock
Moving against COSCIENS Stock
| 0.34 | MRK | Merck Company Aggressive Push | PairCorr |
| 0.31 | ABBV | AbbVie Inc | PairCorr |
| 0.34 | WMT | Walmart Common Stock Aggressive Push | PairCorr |
Related Correlations Analysis
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between COSCIENS Stock performing well and COSCIENS Biopharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze COSCIENS Biopharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| BIOR | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| TSBX | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| CRVO | 3.04 | 0.08 | 0.01 | 0.21 | 3.60 | 6.31 | 17.75 | |||
| CHRO | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| TVRD | 4.23 | (1.59) | 0.00 | 1.06 | 0.00 | 7.65 | 99.32 | |||
| OMGA | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| TNFA | 8.70 | (0.75) | 0.00 | (0.62) | 0.00 | 17.75 | 79.44 | |||
| APGN | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| KA | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
COSCIENS Biopharma Corporate Management
| Michel Eng | MD operations | Profile | |
| Matthias Gerlach | Senior Production | Profile | |
| Nicola MD | Chief Development | Profile | |
| Anna Biehn | Chief Officer | Profile | |
| Michael Teifel | Senior Officer | Profile |